Old Web
English
Sign In
Acemap
>
authorDetail
>
Kathrin Petersdorf
Kathrin Petersdorf
Bayer
Vilaprisan
Uterine fibroids
Medicine
Obstetrics
Clinical trial
4
Papers
26
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation.
2021
British Journal of Clinical Pharmacology
Gabriele Sutter
Matthias Frei
Marcus-Hillert Schultze-Mosgau
Kathrin Petersdorf
Christian Seitz
Bart Ploeger
Show All
Source
Cite
Save
Citations (3)
Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2
2020
European Journal of Obstetrics & Gynecology and Reproductive Biology
Kristina Gemzell-Danielsson
Oskari Heikinheimo
János Zatik
Róbert Póka
Tomasz Rechberger
Robert Hudeček
Kathrin Petersdorf
Francisco Ramírez
T. Faustmann
E. Groettrup-Wolfers
Christian Seitz
Show All
Source
Cite
Save
Citations (5)
Improvement in health-related quality of life (HRQoL) in women with uterine fibroids (Uf) treated with vilaprisan (VPR): a summary of results from asteroid 1 and 2
2019
Fertility and Sterility
Claudia Haberland
Kathrin Petersdorf
Uwe Mellinger
Christoph Gerlinger
Linda D. Bradley
Kristina Gemzell-Danielsson
Sukhbir S. Singh
Christian Seitz
Show All
Source
Cite
Save
Citations (0)
Vilaprisan in Women with Uterine Fibroids: The Randomized Phase 2b ASTEROID 1 Study.
2019
Fertility and Sterility
Linda D. Bradley
Sukhbir S. Singh
James A. Simon
Kristina Gemzell-Danielsson
Kathrin Petersdorf
Esther Groettrup-Wolfers
Xiaowei Ren
Michal Zvolanek
Christian Seitz
Show All
Source
Cite
Save
Citations (18)
1